Arca
Skip to content
Tools
Tools

PIK3CD: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol (PI) and its phosphorylated derivatives at position 3 of the inositol ring to produce 3-phosphoinositides.

  • Drugs that act on it: 17
  • Approved: 5
  • In phases 1 to 3: 12
  • Sponsors: 15

Who Is On It, and How Far Along

Every drug ChEMBL records acting on PIK3CD, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Other

Approved5

  • Copanlisib
  • Duvelisib
  • Idelalisib
  • Leniolisib
  • Umbralisib

Phase 32

  • Parsaclisib
  • Zandelisib

Phase 28

  • Fimepinostat
  • Tenalisib
  • Acalisib
  • AMG-319
  • INCB-40093
  • Nemiralisib
  • Seletalisib
  • TG100-115

Phase 12

  • AZD-8186
  • CAL-263

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

  • Curis, Inc.16%
  • Incyte Biosciences Japan GK16%
  • MEI Pharma, Inc.16%

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule1588%
  • Other212%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: PI3-kinase p110-delta subunit inhibitor.
CopanlisibApprovedBayerSmall moleculeInhibitor—15—
DuvelisibApprovedSecura BioSmall moleculeInhibitor—15Boxed warning
IdelalisibApprovedGilead SciencesSmall moleculeInhibitor—7Boxed warning
LeniolisibApprovedPharming GroupSmall moleculeInhibitor—4—
UmbralisibApprovedTG TherapeuticsSmall moleculeInhibitor—4Withdrawn
ParsaclisibPhase 3Incyte Biosciences Japan GKSmall moleculeInhibitor—4—
ZandelisibPhase 3MEI Pharma, Inc.Small moleculeInhibitor—0—
FimepinostatPhase 2Curis, Inc.Small moleculeInhibitor—1—
TenalisibPhase 2Rhizen Pharmaceuticals SASmall moleculeInhibitor—1—
AcalisibPhase 2Gilead SciencesSmall moleculeInhibitor—0—
AMG-319Phase 2AmgenSmall moleculeInhibitor—0—
INCB-40093Phase 2IncyteOtherInhibitor—0—
NemiralisibPhase 2GSKSmall moleculeInhibitor—0—
SeletalisibPhase 2UCB CelltechSmall moleculeInhibitor—0—
TG100-115Phase 2TargeGenSmall moleculeInhibitor—0—
AZD-8186Phase 1AstraZeneca PharmaceuticalsSmall moleculeInhibitor—0—
CAL-263Phase 1Gilead SciencesOtherInhibitor—0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 37 in all, from ClinicalTrials.gov.
A Study of Topical Duvelisib in Participants With Early-stage Mycosis FungoidesDuvelisibPhase 1Not yet recruitingSecuraBio2026-07-20
Duvelisib Maintenance for the Treatment of Peripheral T-Cell LymphomasDuvelisibPhase 2RecruitingCity of Hope Medical Center2025-12-19
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaIdelalisibPhase 4RecruitingEli Lilly and Company2025-10-20
A Single-arm Phase 2 Prospective Clinical Study of Linprixel in the Treatment of Relapsed/Refractory Autoimmune Hemolytic AnemiaParsaclisib—Not yet recruitingPeking Union Medical College Hospital2025-09-02
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)IdelalisibPhase 3RecruitingDizal Pharmaceuticals2025-08-24
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)DuvelisibPhase 1RecruitingMemorial Sloan Kettering Cancer Center2025-06-03
Long-term Safety and Efficacy of Leniolisib in PIDs With Immune DysregulationLeniolisibPhase 2Active, not recruitingPharming Technologies B.V.2025-05-25
A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) InhibitorsIdelalisibPhase 3RecruitingBeOne Medicines2025-02-26
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)DuvelisibPhase 1 / Phase 2RecruitingJonsson Comprehensive Cancer Center2025-02-06
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary FibrosisIdelalisibPhase 2Active, not recruitingCalluna Pharma AS2024-12-17
New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ SyndromeLeniolisib—RecruitingAssistance Publique - Hôpitaux de Paris2024-11-19
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasDuvelisibPhase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, China2024-07-31
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeDuvelisibPhase 3RecruitingSecuraBio2024-07-26
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)CopanlisibPhase 2Active, not recruitingNational Cancer Institute (NCI)2024-05-06
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)CopanlisibPhase 2Active, not recruitingNational Cancer Institute (NCI)2024-04-11
Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)TenalisibPhase 2RecruitingRhizen Pharmaceuticals SA2024-01-03
Prospective, Single Arm, Single Center Study of Duvelisib Combined With Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma (PTCL)DuvelisibPhase 2RecruitingLiling Zhang2023-08-04
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing DiseaseFimepinostatPhase 2RecruitingUniversity of California, Los Angeles2023-08-02
(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)Duvelisib—Not yet recruitingRuijin Hospital2023-06-28
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerIdelalisibPhase 2RecruitingOslo University Hospital2023-02-13
Pediatric Patients Aged 1 to 6 Years With APDSLeniolisibPhase 3Active, not recruitingPharming Technologies B.V.2023-01-20
Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)CopanlisibPhase 2Active, not recruitingNational Cancer Institute (NCI)2022-08-08
Pediatric Patients Aged 4 to 11 Years With APDSLeniolisibPhase 3Active, not recruitingPharming Technologies B.V.2022-06-30
Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell LymphomaCopanlisibPhase 1 / Phase 2Active, not recruitingCity of Hope Medical Center2021-06-25
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell LymphomaUmbralisibPhase 2Active, not recruitingCity of Hope Medical Center2021-03-05
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)IdelalisibPhase 3Active, not recruitingLoxo Oncology, Inc.2020-12-14
To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)ParsaclisibPhase 1 / Phase 2Active, not recruitingIncyte Biosciences Japan GK2020-12-09
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLLUmbralisibPhase 2Active, not recruitingJennifer R. Brown, MD, PhD2020-11-12
Copanlisib Plus Venetoclax in R/R DLBCLCopanlisibPhase 1 / Phase 2Active, not recruitingDana-Farber Cancer Institute2020-10-01
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)ParsaclisibPhase 2Active, not recruitingIncyte Corporation2020-08-12
Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerCopanlisibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)2020-04-15
Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell LymphomaParsaclisibPhase 1Active, not recruitingMayo Clinic2020-03-27
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTENCopanlisibPhase 1 / Phase 2Active, not recruitingNational Cancer Institute (NCI)2020-03-23
A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate CancerCopanlisibPhase 1 / Phase 2Active, not recruitingBrown University2020-02-05
Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLUmbralisibPhase 1Active, not recruitingUniversity of Chicago2017-09-14
Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular LymphomaUmbralisibPhase 2Active, not recruitingNational Cancer Institute (NCI)2017-09-01
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLIdelalisibPhase 3Active, not recruitingAcerta Pharma BV2016-11-22

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Activated PI3K-delta syndrome
0.76
Immunodeficiency 14b, autosomal recessive
0.69
Combined immunodeficiency with faciooculoskeletal anomalies
0.61
Neoplasm
0.58
Neoplasm of mature B-cells
0.53
Marginal zone lymphoma
0.52
Combined immunodeficiency
0.46
Inborn error of immunity
0.45

Genes and Related Targets

Complexes and families that share a gene with this target
Genes
PIK3CD

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3130, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt O00329, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.